Tag: rivaroxaban

1. At a median follow-up of 3.3 years, rates of symptomatic venous thromboembolism or death due to thromboembolism were similar for medically ill patients treated with rivaroxaban or placebo for 45 days following hospital discharge. 2. Major bleeding events occurred at similar rates for rivaroxaban or placebo treated patients. Evidence Rating...
1. At a median follow-up of eleven months, rivaroxaban was not superior to aspirin for prevention of secondary stroke after an initial primary embolic stroke of undetermined source. 2. Use of rivaroxaban was associated with a higher rate of major bleeding relative to aspirin. Evidence Rating Level: 1 (Excellent) Study Rundown: Improvements...
1. Patients initially treated with rivaroxaban following total knee or hip arthroplasty experienced similar rates of venous thromboembolism (VTE) regardless of continued rivaroxaban use or switching to aspirin for extended VTE prophylaxis. 2. No significant difference in rates of major bleeding complications was observed between aspirin and rivaroxaban treated groups. Evidence...
1. The EINSTEIN CHOICE trial involved patients who had a history of venous thromboembolism (VTE) and had completed 6 to 12 months of therapeutic anticoagulation and were in equipoise regarding the need for continued anticoagulation. 2. In this population, rivaroxaban at a dose of 20 mg or 10 mg daily...
1. In patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI), treatment with rivaroxaban, in addition to dual antiplatelet therapy (DAPT), led to significantly lower rates of clinically significant bleeding compared to treatment with DAPT and dose-adjusted vitamin K antagonist. 2. There were no significant differences between the...
1. Based on a retrospective cohort study of US Medicare patients, rivaroxaban was associated with a significantly increased risk of intracranial and extracranial hemorrhage compared with dabigatran when used in elderly patients with nonvalvular atrial fibrillation for stroke prevention. 2. There was a trend towards a decrease in thromboembolic stroke...
Classics Series, Landmark Trials in Medicine
Image: PD 1. Rivaroxaban, an oral factor Xa inhibitor, was non-inferior to standard anticoagulation therapy (i.e. low-molecular weight heparin and a vitamin K antagonist) in the prevention of recurrent thromboembolism following a pulmonary embolism. 2. The rate of major bleeding was significantly lower with rivaroxaban than with standard anticoagulant therapy. Original Date...
Image: PD 1. Rivaroxaban is non-inferior to standard therapy of enoxaparin and vitamin K antagonist in treating acute, symptomatic deep-vein thrombosis 2. The risk of major and clinically relevant nonmajor bleeding was not significantly different when comparing rivaroxaban with standard therapy Original Date of Publication: December 23, 2010 Study Rundown: The EINSTEN-DVT trial demonstrated...
Feb 6th - NEJM - Extended-duration rivaroxaban was superior to standard-duration enoxaparin for thromboprophylaxis, but was associated with increased bleeding risk. Image: PD 1. Standard-duration rivaroxaban had no net clinical benefit over standard-duration enoxaparin for thromboprophylaxis in acutely ill hospitalized patients. 2. Extended-duration rivaroxaban was superior to standard-duration enoxaparin for thromboprophylaxis, but...
Classics Series, Landmark Trials in Medicine
1. Rivaroxaban is non-inferior to warfarin in preventing strokes and systemic embolism. 2. Although there is no significant difference between the two in the incidence of clinically relevant bleeding, rivaroxaban is associated with significantly lower rates of critical, fatal, and intracranial bleeding. Original Date of Publication: September 8, 2011 Study Rundown: Warfarin has...